- Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
- Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
- Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
- Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
- Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022
More ▼
Key statistics
On Friday, Relmada Therapeutics Inc (RLMD:NSQ) closed at 4.12, 127.62% above the 52 week low of 1.81 set on Dec 08, 2022.
52-week range
Markit short selling activity
Open | 4.22 |
---|---|
High | 4.45 |
Low | 4.07 |
Bid | 4.05 |
Offer | 4.60 |
Previous close | 4.27 |
Average volume | 276.57k |
---|---|
Shares outstanding | 30.10m |
Free float | 29.71m |
P/E (TTM) | -- |
Market cap | 124.01m USD |
EPS (TTM) | -5.85 USD |
Data delayed at least 15 minutes, as of Feb 03 2023 21:00 GMT.
More ▼